- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04198766
Étude de l'INBRX-106 et de l'INBRX-106 en association avec le pembrolizumab chez des sujets atteints de tumeurs solides localement avancées ou métastatiques (agoniste hexavalent OX40)
Une étude ouverte, multicentrique, première chez l'homme, à dose croissante, de phase 1 portant sur l'INBRX-106 et l'INBRX-106 en association avec le pembrolizumab chez des sujets atteints de tumeurs solides localement avancées ou métastatiques
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
- Médicament: INBRX-106 - Hexavalent OX40 agonist antibody
- Médicament: pembrolizumab 200 mg
- Médicament: pembrolizumab 400 mg
- Médicament: Carboplatin AUC-5
- Médicament: Pemetrexed 500 mg/m2
- Médicament: Cisplatin 75mg/m2
- Médicament: Carboplatin AUC-6
- Médicament: Paclitaxel 200mg/m2
- Médicament: Nab paclitaxel 100mg/m2
- Médicament: Gemcitabine (1000 mg/m2)
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Study Director - Inhibrx Biosciences, Inc
- Numéro de téléphone: 858-500-7833
- E-mail: clinicaltrials@inhibrx.com
Lieux d'étude
-
-
-
Busan, Corée du Sud
- Pas encore de recrutement
- Inje University College of Medicine
-
Chercheur principal:
- IL-Hwan Kim, MD, PhD
-
Cheongju-si, Corée du Sud
- Pas encore de recrutement
- Chungbuk National University Hospital
-
Chercheur principal:
- Ki-Hyeong Lee, MD
-
Gyeonggi-do, Corée du Sud
- Recrutement
- The Catholic University of Korea, St. Vincent's Hospital
-
Chercheur principal:
- Byoung Yong Shim
-
Hwasun, Corée du Sud
- Pas encore de recrutement
- Chonnam National University Hwasun Hospital
-
Chercheur principal:
- In-Jae Oh, MD, MS, PhD
-
Incheon, Corée du Sud
- Pas encore de recrutement
- Gachon University Gil Medical Center
-
Chercheur principal:
- Eun Kyung Cho, PhD, M.S
-
Seongnam-si, Corée du Sud
- Pas encore de recrutement
- CHA Bundang Medical Center
-
Chercheur principal:
- Yoon Beom Sang
-
Seoul, Corée du Sud
- Recrutement
- Asan Medical Center
-
Contact:
- Bokyeong Jung, RN
- E-mail: bokyeong_jung@amc.seoul.kr
-
Chercheur principal:
- Dae Ho Lee, MD
-
Seoul, Corée du Sud
- Recrutement
- Severance Hospital, Yonsei University Health System
-
Contact:
- Miyeon Lee
- E-mail: lee_my@yuhs.ac
-
Chercheur principal:
- Sun Mun Lim
-
Seoul, Corée du Sud
- Recrutement
- The Catholic University of Korea Seoul St. Mary's Hospital,
-
Chercheur principal:
- SookHee Hong
-
Contact:
- Na Ayn
- E-mail: Ahnna331@gmail.com
-
Seoul, Corée du Sud
- Pas encore de recrutement
- Korea University Anam Hospital
-
Chercheur principal:
- Yoon Ji Choi, MD, MS, PhD
-
Seoul, Corée du Sud
- Pas encore de recrutement
- Hanyang University Seoul Hospital
-
Chercheur principal:
- Myung- Ju Ahn, MD, PhD, MS
-
Seoul, Corée du Sud
- Pas encore de recrutement
- Korea University Guro Hospital
-
Chercheur principal:
- Sung Yong Lee
-
Chercheur principal:
- Sung Yong Lee, MD, MS, PhD
-
Suwon, Corée du Sud
- Pas encore de recrutement
- Ajou University Hospital
-
Chercheur principal:
- Yong-Won Choi, MD
-
-
-
-
-
Singapore, Singapour
- Complété
- Curie Oncology
-
Singapore, Singapour
- Complété
- Icon Cancer Centre Farrer Park
-
Singapore, Singapour
- Complété
- Icon Cancer Centre Mount Alvernia
-
-
-
-
-
Changhua, Taïwan
- Actif, ne recrute pas
- Changhua Christian Hospital (CCH)
-
Kaohsiung City, Taïwan
- Actif, ne recrute pas
- E-Da Cancer Hospital
-
Kaohsiung City, Taïwan
- Actif, ne recrute pas
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH)
-
Tainan, Taïwan
- Actif, ne recrute pas
- National Cheng Kung University Hospital
-
Taipei, Taïwan
- Complété
- Taipei Veterans General Hospital
-
-
-
-
California
-
Duarte, California, États-Unis, 91010
- Actif, ne recrute pas
- City of Hope
-
Glendale, California, États-Unis, 91204
- Recrutement
- Oncura Health
-
Contact:
- Elizabeth Brown
- E-mail: Elizabeth.Brown@lahomg.com
-
Chercheur principal:
- Sungwon Kyung, MD
-
La Jolla, California, États-Unis, 92037
- Pas encore de recrutement
- UC San Diego Health - Moores Cancer Center
-
Chercheur principal:
- Lyudmila Bazhenova, MD
-
Los Angeles, California, États-Unis, 90027
- Recrutement
- California Research Institute
-
Chercheur principal:
- Ghassan Al-Jazayrly, MD
-
Contact:
- Swati Shrestha
- E-mail: sw@caresinst.com
-
Los Angeles, California, États-Unis, 90069
- Recrutement
- Valkyrie Clinical Trials
-
Chercheur principal:
- David Berz, MD
-
Contact:
- Myo Zaw
- E-mail: myo.zaw@valkyrieclinicaltrials.com
-
Los Angeles, California, États-Unis, 90033
- Pas encore de recrutement
- University of Southern California Norris Comprehensive Cancer Center
-
Chercheur principal:
- Jorge Nieva, MD
-
Murrieta, California, États-Unis, 92562
- Recrutement
- Valkyrie Clinical Trials
-
Chercheur principal:
- David Berz, MD
-
Contact:
- Isabella Gudino
- E-mail: Isabella.gudino@vctcare.com
-
Santa Rosa, California, États-Unis, 95403
- Recrutement
- Providence Medical Foundation
-
Chercheur principal:
- Ian Anderson, MD
-
Contact:
- Clinical Research Coordinator
- Numéro de téléphone: 1181 707-521-3810
- E-mail: jackson.barnard@providence.org
-
-
Colorado
-
Lakewood, Colorado, États-Unis, 80228
- Pas encore de recrutement
- Valkyrie Clinical Trials - Colorado
-
Chercheur principal:
- Jason Henry, MD
-
-
Florida
-
Clermont, Florida, États-Unis, 34711
- Recrutement
- Clermont Oncology Center
-
Chercheur principal:
- Gopal Kunta, MD
-
Contact:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
Orange City, Florida, États-Unis, 32763
- Recrutement
- Mid Florida Hematology and Oncology Center
-
Chercheur principal:
- Santosh Nair, MD
-
Contact:
- Kiran Penta
- E-mail: kiran@aorcorp.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Actif, ne recrute pas
- Winship Cancer Institute - Emory University
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Pas encore de recrutement
- University of Illinois Cancer Center
-
Chercheur principal:
- Frank Weinberg, MD, PhD
-
Chicago, Illinois, États-Unis, 60637
- Actif, ne recrute pas
- The University of Chicago Medical Center
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- Recrutement
- University of Iowa
-
Chercheur principal:
- Douglas Laux, MD
-
Contact:
- Jordan Harrelson
- Numéro de téléphone: 319-467-5831
- E-mail: Jordan-harrelson@uiowa.edu
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40202
- Recrutement
- Norton Cancer Institute
-
Chercheur principal:
- John Hamm, MD
-
Contact:
- Jenn Broadway, RN
- Numéro de téléphone: 19535 502-629-2500
- E-mail: Jennifer.Broadway@nortonhealthcare.org
-
-
Michigan
-
Detroit, Michigan, États-Unis, 48202
- Recrutement
- Henry Ford Cancer Institute
-
Chercheur principal:
- Amy Weise, MD
-
Contact:
- Mahmoud Hossami
- Numéro de téléphone: 313-725-7842
- E-mail: mhossam1@hfhs.org
-
Detroit, Michigan, États-Unis, 48201
- Complété
- Barbara Ann Karmanos Cancer Institute
-
Grand Rapids, Michigan, États-Unis, 49546
- Actif, ne recrute pas
- START Midwest
-
-
Minnesota
-
Saint Louis Park, Minnesota, États-Unis, 55426
- Actif, ne recrute pas
- HealthPartners Cancer Research Center
-
Saint Paul, Minnesota, États-Unis, 55101
- Complété
- HealthPartners Cancer Research Center (Regions Hospital)
-
-
Missouri
-
St Louis, Missouri, États-Unis, 63110
- Pas encore de recrutement
- Washington University in St. Louis School of Medicine
-
Chercheur principal:
- Brett Herzog, MD, PhD
-
-
Montana
-
Billings, Montana, États-Unis, 59102
- Complété
- Intermountain Health Cancer Centers of Montana
-
-
Nebraska
-
Grand Island, Nebraska, États-Unis, 68803
- Pas encore de recrutement
- Nebraska Cancer Specialists - Grand Island
-
Chercheur principal:
- Ralph Hauke, MD
-
Omaha, Nebraska, États-Unis, 68130
- Recrutement
- Nebraska Cancer Specialists
-
Chercheur principal:
- Ralph Hauke, MD
-
Contact:
- Lindsey Becker
- Numéro de téléphone: 402-691-5255
- E-mail: lbecker@nebraskacancer.com
-
-
New Jersey
-
Camden, New Jersey, États-Unis, 08103
- Pas encore de recrutement
- MD Anderson Cancer Center at Cooper
-
Chercheur principal:
- Polina Khrizman, MD
-
-
New York
-
The Bronx, New York, États-Unis, 10467
- Actif, ne recrute pas
- Montefiore Medical Center
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Actif, ne recrute pas
- Cleveland Clinic
-
-
Oregon
-
Portland, Oregon, États-Unis, 97213
- Actif, ne recrute pas
- Providence Portland Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Pas encore de recrutement
- Lehigh Valley Health Network
-
Chercheur principal:
- Muhammad Rizvi, MD
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37923
- Pas encore de recrutement
- University of Tennessee Health Science Center
-
Chercheur principal:
- Sean Jordan, MD
-
Nashville, Tennessee, États-Unis, 37204
- Actif, ne recrute pas
- Vanderbilt University School of Medicine
-
-
Texas
-
Dallas, Texas, États-Unis, 75230
- Complété
- Sarah Cannon Research Institute at Mary Crowley
-
El Paso, Texas, États-Unis, 79915
- Complété
- Renovatio Clinical - El Paso
-
San Antonio, Texas, États-Unis, 78229
- Complété
- NEXT Oncology
-
The Woodlands, Texas, États-Unis, 77380
- Complété
- Renovatio Clinical
-
Tyler, Texas, États-Unis, 75701
- Recrutement
- The University of Texas Health Science Center at Tyler
-
Contact:
- Chaney Story
- E-mail: Chaney.Story@uttyler.edu
-
Chercheur principal:
- Erminia Massarelli, MD, PhD, MS
-
-
Virginia
-
Fairfax, Virginia, États-Unis, 22031
- Complété
- Virginia Cancer Specialists
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Recrutement
- Froedtert Hospital and the Medical College of Wisconsin
-
Chercheur principal:
- Jonathan Thompson, MD
-
Contact:
- Ellen Smith
- E-mail: eksmith@mcw.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Select Inclusion Criteria:
- Males or females aged ≥18 years.
- Parts 1 and 3 (escalation cohorts): Subjects with locally advanced or metastatic non resectable solid tumors, whose disease has progressed despite all standard therapies or for whom no further standard or clinically acceptable therapy exists.
- Part 2 (single-agent expansion cohort): Subjects with NSCLC, melanoma, HNSCC, G/GEA, RCC, or TCC, with histologically confirmed, locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists.
- Part 4 (expansion cohorts in combination with pembrolizumab, with or without chemotherapy): Subjects with melanoma (all types), HNSCC, G/GEA, RCC, TCC, NSCLC, or MSI-high, TMB-high, MMR-deficient tumors, with histologically confirmed, locally advanced or metastatic, non resectable disease, which is either CPI-naive (melanoma, HNSCC, NPC) or progressed despite all standard therapies including CPI (NSCLC, RCC, TCC, uveal melanoma, MSI-high, TMB-high, or MMR-deficient solid tumors) or for whom no standard or clinically acceptable therapy exists.
- For Cohort F3 (NSCLC), subjects may have progressed on no more than 2 lines of standard therapy that must include at least one PD-1/L1 regimen.
- For Cohort F4 (HNSCC and NPC), subjects may be previously treated with no more than 1 prior chemotherapy regimen in metastatic setting. Prior PD-1/L1 in curative (neo-adjuvant/adjuvant) setting is allowed only if completed >/= 6 months prior to progression to local recurrence or metastatic disease.
- For Cohort F8, subjects must have previously untreated, histologically confirmed Stage II, IIIA or IIIB (T3-4N2) NSCLC. Lymph node disease requires histologic confirmation, while T3 disease requires only radiographic documentation. Subjects need to be able to undergo planned surgery.
- All subjects with non-squamous NSCLC must have documentation of absence of tumor activating EGFR mutations and absence of ALK gene rearrangements.
- PD-L1 by IHC (22C3): Parts 1 and 3: IHC optional. Part 2: IHC result mandatory but any score allowed. Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). Part 4: Combined Positive Score (CPS) ≥ 1% (or Tumor Proportion Score ≥50% for NSCLC; for TMB-high tumors, any TPS% is allowed). For Cohort F8, any TPS (including 0%) is acceptable.
- Adequate hematologic, coagulation, hepatic and renal function and ECOG score as defined per protocol.
Select Exclusion Criteria:
- Prior exposure to OX40 agonists. Exposure to anti-PD-1 and/or anti PD-L2 CPIs or an agent targeting other co-stimulatory T-cell receptor pathways.
- Receipt of any investigational product or any approved anticancer drug(s) or biological product(s) within 4 weeks prior to the first dose of study drug with certain exceptions.
- Hematologic malignancies (e.g., ALL, AML, MDS, CLL, CML, NHL, Hodgkin's lymphoma and multiple myeloma)
- Prior or concurrent malignancies. Exception: Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessments of INBRX-106.
- Grade ≥ 3 immune-related adverse events (irAEs) or irAE that lead to discontinuation of prior immunotherapy. Some exceptions as defined per protocol apply.
- Active autoimmune disease or documented history of autoimmune disease that required systemic steroids or other immunosuppressive medications. Certain exceptions as defined in protocol apply.
- Diagnosis of immunodeficiency or treatment with systemic immunosuppressive medications within 7 days prior to the first dose of study drug. Certain exceptions as defined in protocol apply.
- History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection. Exceptions as defined in protocol apply.
- Active interstitial lung disease (ILD) or pneumonitis or a history of ILD or pneumonitis requiring treatment with steroids or other immunosuppressive medications.
- Clinically significant cardiac condition, including myocardial infarction, uncontrolled angina, viral myocarditis, cerebrovascular accident, or other acute uncontrolled heart disease < 3 months prior to enrollment on this trial; left ventricular ejection fraction (LVEF) < 50%; New York Heart Association (NYHA) Class III or IV congestive heart failure; or uncontrolled hypertension; or oxygen saturation <92% on room air.
- Active, hemodynamically significant pulmonary embolism within 12 weeks prior to enrollment on this trial.
- Major surgery within 4 weeks prior to enrollment on this trial.
- Anti-infectious drug treatments (i.e., antibiotics) within 4 weeks prior to the first dose of study drug.
- Prior organ allograft transplantations or allogeneic peripheral blood stem cell (PBSC) or bone marrow (BM) transplantation.
- Additional in- and exclusion criteria per protocol.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Part 1 INBRX-106 Escalation (Not Recruiting)
INBRX-106 will be escalated in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Expérimental: Part 3 INBRX-106 Escalation in Combination with pembrolizumab (Not Recruiting)
INBRX-106 will be escalated, in combination with pembrolizumab, in subjects with locally advanced or metastatic solid tumors. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Part 2 (Cohorts C1/C2) INBRX-106 Escalation in Various Solid Tumor Types (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma or MSI/TMB-high tumors that are relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Part 2 (Cohort C3) INBRX-106 Escalation in NSCLC (Not Recruiting)
Subjects with non-small cell carcinoma relapsed or refractory to prior checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 |
pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Part 4 (Cohort F3a) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with alternating dosing of INBRX-106 0.3 mg/kg Q6W and 400 mg pembrolizumab IV Q6W. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Autres noms:
|
|
Expérimental: Part 4 (Cohort F3b) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not Recruiting)
Subjects with non-small cell lung cancer will be given a 0.3 mg/kg priming dose of INBRX-106 in cycle 1, followed by 0.1 mg/kg INBRX-106 and 200 mg pembrolizumab IV every 3 weeks in subsequent cycles. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
pembrolizumab 400 mg by IV infusion given on Day 1 of alternating 21-day cycles (every 6 weeks)
Autres noms:
|
|
Comparateur actif: Part 4 (Cohort F3c) Pembrolizumab Expansion Arm (Not Recruiting)
Subjects with non-small cell lung cancer will be treated with 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Expérimental: Part 4 (Cohort F3d) INBRX-106 Expansion in Combination with pembrolizumab in NSCLC (Not-Recruiting)
Subjects with non-small cell lung cancer will be treated concurrently every 6 weeks with INBRX-106 0.1 mg/kg and 200 mg pembrolizumab IV every 3 weeks. This is one of the randomized cohorts. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). |
|
Expérimental: Part 4 (Cohort F4) INBRX-106 Expansion in Combination with pembrolizumab (Not Recruiting)
Subjects with melanoma (any type), head and neck squamous cell carcinoma (non-nasopharyngeal) OR nasopharyngeal carcinoma, MSI-high, TMB-high or MMR-deficient tumors, will be treated with INBRX-106 in combination with 200mg pembrolizumab IV every 3 weeks. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Part 4 (Cohort F5)INBRX-106 Expansion with pembrolizumab in MSI/TMB-high/MMRd tumors Not Recuriting
Subjects with solid tumors that have confirmed MSI-high, TMB-high or MMR-deficient states who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Part 4 (Cohort F6) INBRX-106 Expansion with pembrolizumab in Uveal Melanoma (Not Recruiting)
Subjects with ocular (uveal) melanoma who are relapsed or refractory to checkpoint inhibitor (CPI) therapy will be treated with INBRX-106 and 200 mg pembrolizumab IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Autres noms:
|
|
Expérimental: Part 4 (Cohort F7a) INBRX-106 Expansion with pembrolizumab, pemetrexed and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and carboplatin AUC-5 IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Autres noms:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 |
|
Expérimental: Part 4 (Cohort F7b) INBRX-106 Expansion with pembrolizumab, pemetrexed and cisplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 500mg/m2 pemetrexed and 75mg/m2 cisplatin IV every 3 weeks |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
carboplatin AUC-6 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 paclitaxel 200mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Nab paclitaxel 100mg/m2 by intravenous (IV) infusion, given on Days 1, 8 and 15 of each 21-day cycle of cycles 1-4 |
|
Expérimental: Part 4(Cohort F7c)INBRX-106 Expansion with pembrolizumab, (Nab)-paclitaxel and carboplatin in NSCLC
This Arm is no longer recruiting. Subjects with advanced/metastatic NSCLC, any PD-L1 TPS will be treated with INBRX-106 0.1mg/kg, 200mg pembrolizumab, 200mg/m2 paclitaxel and carboplatin AUC-6 IV every 3 weeks OR INBRX-106, 200mg pembrolizumab, 100mg/m2 nab-paclitaxel (dosed Days 1,8 and 15 every cycle) and carboplatin AUC-6 IV every 3 weeks. Treating physician to determine if paclitaxel or nab-paclitaxel will be given |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
|
|
Expérimental: Part 4(Cohort F8)INBRX-106 with pembrolizumab, cisplatin and gemcitabine or pemetrexed in NSCLC
Subjects with resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC , any PD-L1 TPS will receive neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 (dosed Day 1 only) with gemcitabine 1000 mg/m2 (dosed on Days 1 and 8) for patients with squamous cell NSCLC given every 3 weeks OR neoadjuvant treatment with INBRX-106 0.1 mg/kg, 200 mg pembrolizumab, cisplatin 75 mg/m2 with pemetrexed 500 mg/m2 for patients with non-squamous cell NSCLC given every 3 weeks. Carboplatin AUC5 (dosed on Day 1 only) can be substituted for Cisplatin for subjects who are clinically considered ineligible or unsuitable for cisplatin per the Investigator's discretion or institution SOPs. Neoadjuvant treatment will be given for up to 4 cycles followed by surgery (lobectomy, bilobectomy or pneumonectomy). After surgery, all patients will receive adjuvant treatment consisting of INBRX-106 0.1 mg/kg, 200 mg pembrolizumab given every 3 weeks for up to 13 cycles. |
The active ingredient of INBRX-106 is a recombinant, humanized, hexavalent IgG antibody that targets the human OX40 receptor (TNFRSF4). pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Autres noms:
carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4. Cohort F8, carboplatin AUC-5 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycle 2-4. pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle for up to 35 cycles. In Cohort F8, pemetrexed 500 mg/m2 by IV infusion given on Day 1 of each 21-Day cycle of cycles 1-4.
Autres noms:
cisplatin 75mg/m2 by intravenous (IV) infusion, given on Day 1 of each 21-day cycle of cycles 1-4 Gemcitabine 1000 mg/m2 given by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle of cycles 1-4 |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Frequency of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Délai: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
Severity of adverse events of INBRX-106 as single agent and in combination with pembrolizumab
Délai: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
MTD and/or RP2D of INBRX-106 as single agent and in combination with pembrolizumab
Délai: ~2 years
|
Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of INBRX-106 and INBRX-106 in combination with pembrolizumab |
~2 years
|
|
Antitumor activity of INBRX-106 in combination with pembrolizumab in expansion cohorts
Délai: ~2 years
|
The evaluation of efficacy will be based on the subject's measurable disease using RECIST v1.1 |
~2 years
|
|
Frequency and severity of adverse events of INBRX-106 in combination with pembrolizumab and chemotherapy in adults with locally advanced or metastatic NSCLC or resectable Stage II, IIIA or IIIB (T3-4N2) NSCLC
Délai: ~2 years
|
Adverse events will be assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0 |
~2 years
|
|
To assess the antitumor activity of INBRX-106 in combination with pembrolizumab and platinum doublet chemotherapy as neoadjuvant/adjuvant therapy in adult subjects with NSCLC. (Cohort F8)
Délai: ~2 years
|
Major pathological response (mPR) and pathological complete response (cPR) criteria. |
~2 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Area under the serum concentration time curve (AUC) of INBRX-106
Délai: ~2 years
|
Area under the serum concentration time curve (AUC) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Maximum observed serum concentration (Cmax) of INBRX-106
Délai: ~2 years
|
Maximum observed serum concentration (Cmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Trough observed serum concentration (Ctrough) of INBRX-106
Délai: ~2 years
|
Trough observed serum concentration (Ctrough) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Time to Cmax (Tmax) of INBRX-106
Délai: ~2 years
|
Time to Cmax (Tmax) of INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
|
Immunogenicity of INBRX-106
Délai: ~2 years
|
Frequency of anti-drug antibodies (ADA) against INBRX-106 as a single agent and in combination with pembrolizumab with or without chemotherapy will be determined. |
~2 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Délai: ~2 years
|
Tumor response will be determined by the revised Response Evaluation Criteria in Solid Tumors version 1.1 (RECISTv1.1). |
~2 years
|
|
Anti-tumor activity of INBRX-106 as single agent and in combination with pembrolizumab with or without chemotherapy
Délai: ~2 years
|
Tumor response will be determined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1). |
~2 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Clinical Lead, Inhibrx Biosciences, Inc
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
- Cancer de la tête et du cou
- Cancer du poumon
- NSCLC
- Cancer du poumon non à petites cellules
- Carcinome
- Tumeurs
- Immunothérapie
- Pembrolizumab
- Chimiothérapie
- Keytruda
- HNSCC
- Néoadjuvant
- Agents antinéoplasiques
- Adjuvant
- Tumeurs solides
- Cancer de la bouche
- Cancer de l'oropharynx
- INBRX-106
- Agents antinéoplasiques immunologiques
- Tumeurs de la tête et du cou
- Tumeurs, glandulaires et épithéliales
- Tumeurs par type histologique
- Tumeurs par site
- Carcinome épidermoïde de la tête et du cou
- Mécanismes moléculaires de l'action pharmacologique
- PD-L1 positif
- Tumeurs à cellules squameuses
- Carcinome épidermoïde
- Cancer de l'hypopharynx
- Phase 1 et Phase 2
- Essai clinique de phase 1 et de phase 2
- Agoniste des récepteurs OX40
Termes MeSH pertinents supplémentaires
- Maladies urogénitales
- Maladies de la bouche
- Maladies stomatognathiques
- Tumeurs urogénitales
- Maladies urogénitales masculines
- Maladies rénales
- Maladies urologiques
- Maladies urogénitales féminines
- Maladies urogénitales féminines et complications de la grossesse
- Maladies des voies respiratoires
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Maladies de l'estomac
- Maladies pulmonaires
- Adénocarcinome
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Maladies de la peau
- Tumeurs urologiques
- Maladies oto-rhino-laryngologiques
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Tumeurs rénales
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs neuroendocrines
- Tumeurs pharyngées
- Tumeurs oto-rhino-laryngologiques
- Maladies pharyngées
- Nevi et mélanomes
- Tumeurs cutanées
- Maladies de la peau et du tissu conjonctif
- Carcinome épidermoïde de la tête et du cou
- Tumeurs
- Tumeurs de l'estomac
- Carcinome
- Tumeurs pulmonaires
- Carcinome épidermoïde
- Carcinome à cellules rénales
- Carcinome pulmonaire non à petites cellules
- Tumeurs de la tête et du cou
- Mélanome
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Tumeurs à cellules squameuses
- Tumeurs de la bouche
- Carcinome à cellules transitionnelles
- Tumeurs oropharyngées
- Tumeurs par site
- Tumeurs hypopharyngées
- Acides aminés, peptides et protéines
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Hydrocarbures
- Cycloparaffines
- Hydrocarbures, alicyclique
- Hydrocarbures, cyclique
- Terpènes
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Acides aminés, acides
- Acides aminés
- Acides aminés, dicarboxylique
- Taxes
- Cyclodécanes
- Diterpènes
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Économie et organisations des soins de santé
- Composés en platine
- Économie
- Pémétrexed
- Gemcitabine
- Paclitaxel
- Cisplatine
- pembrolizumab
- Taxes
Autres numéros d'identification d'étude
- Ph 1 Ph 2 INBRX-106
- KEYNOTE A99 and MK-3475-A99 (Autre identifiant: Merck Sharp & Dohme LLC)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .